SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Innodata, Inc. is a data engineering company, which engages in providing artificial intelligence software platforms and management of its services. It operates through the following business segments: Digital Data Solutions (DDS), Synodex, and Agility. The DDS segment combines deep neural networks and human expertise in multiple domains to make unstructured information useable. The Synodex segment enables clients in the insurance and healthcare sectors to transform medical records into useable digital data and to apply technologies to the digital data to augment decision support. The Agility segment provides tools and related professional services that enable public relations and communications professionals to discover influencers, amplify messages, monitor coverage, and measure the impact of campaigns. The company was founded by Todd H. Solomon in 1988 and is headquartered in Ridgefield Park, NJ.

Innodata Inc

Innodata (INOD) is trending amid intense community debate surrounding an eagerly anticipated strategic partnership announcement, which the CEO indicated would occur soon, potentially with a defense sector leader. While many bulls foresee this deal solidifying INOD's market leadership in AI data training and government contracts, a vocal skeptical faction expresses frustration over past unfulfilled predictions and general market conditions affecting small-cap AI stocks.

Solana is a highly functional open source project that banks on blockchain technology’s permissionless nature to provide decentralized finance (DeFi) solutions. It is a layer 1 network that offers fast speeds and affordable costs. While the idea and initial work on the project began in 2017, Solana was officially launched in March 2020 by the Solana Foundation with headquarters in Geneva, Switzerland.

Solana

Solana is currently trending due to a surge in cannabis-themed meme coins like $WEEDCOIN, which are seeing significant community-driven gains following reclassification news impacting the sector. While much of the conversation focuses on the bullish momentum and retail frenzy around these specific tokens, the broader community is also discussing Solana's market performance and recent legal developments.

Midnight is a privacy-first blockchain that blends public verifiability with confidential data handling. You can use Midnight's selective disclosure and ZK proofs to build apps.

Midnight

Midnight ($NIGHT) is commanding significant market attention, driven by its current price action and exceptionally high trading volumes. The crypto community is actively debating its privacy-centric utility, strategic position within the Cardano ecosystem, and the effects of recent token distributions. Sentiment ranges from strong bullish predictions to cautious discussions about its long-term sustainability.

UNI is the governance token for Uniswap, an Automated Market Marker DEX on the Ethereum blockchain. The UNI token allows token holders to participate in the governance of the protocol. Key decisions such as usage of the treasury or future upgrades can be decided through a governance vote.

UniSwap

Uniswap is trending amidst strong anticipation for a crucial governance proposal to activate its protocol fee switch and implement a substantial token burn mechanism. The community is actively discussing the potential for the UNI token to become deflationary, which is widely expected to enhance its value and attract significant interest. These proposed changes are seen as a pivotal step toward unlocking new revenue streams for holders and reinforcing Uniswap's strength within the decentralized finance ecosystem.

Exchange Traded Concepts Trust - ROBO Global Robotics and Automation Index ETF

Exchange Traded Concepts Trust - ETCT ROBO Global Robotics and Automation Index ETF

The ROBO Global Robotics and Automation Index ETF is trending as the community eagerly discusses the accelerating physical AI and robotics revolution, bolstered by recent advancements in humanoid robotics and significant investments from industry leaders. Many investors see ROBO as a top diversified vehicle to capitalize on this transformative sector, expecting robots to increasingly address labor needs and redefine industries.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

WEEDCOIN is experiencing a surge in attention, driven by the significant federal reclassification of cannabis, which the community views as a major catalyst for the entire sector. The Solana-based token's strong performance has fueled a retail frenzy, with supporters emphasizing its robust global cannabis culture community and positioning it as a key beneficiary of the shifting regulatory landscape.

Aave is a decentralized money market protocol where users can lend and borrow cryptocurrency across 20 different assets as collateral. The protocol has a native token called AAVE, which is also a governance token that lets the community decide the direction of the protocol in a collective manner. Lenders can earn interest by providing liquidity to the market, while borrowers can borrow by collateralizing their cryptoassets to take out loans from the liquidity pools.

AAVE

Aave is trending as the community highlights its superior product-market fit and aggressive expansion, including the Aave V4 testnet, a new consumer savings app challenging traditional finance, and a proposed $50 million annual token buyback. Community discussion frequently contrasts Aave's strong market share and innovative features with competitors, positioning it as a leading DeFi protocol poised for significant growth and mainstream adoption.

Flora Growth Corp. engages in the production of organic cannabis and pharmaceutical-grade medical products. It operates through the following segments: House of Brands and Commercial and Wholesale. The House of Brands segment includes multiple categories including food and beverage, nutraceuticals, cannabis accessories and technology, personal care and wellness. The Commercial and Wholesale segment includes distribution of pharmaceutical products to international markets. The company was founded on March 13, 2019 and is headquartered in Fort Lauderdale, FL.

Flora Growth Corp

Flora Growth (FLGC) is trending due to its recent pivot and rebranding to ZeroStack, focusing on decentralized AI with a significant crypto treasury of 0G tokens. The community is actively discussing the substantial valuation gap between its reported crypto assets and its micro market capitalization, fueling speculation of a massive short squeeze due to its extremely low float. This strategic shift, alongside shareholder approval for a future forward stock split, has ignited fervent bullish sentiment, drawing comparisons to past high-flying low-float plays.

- Maple is 'DeFi's Institutional Lender'. Maple Finance lending engine powers institutional yield for both Maple and Syrup; providing lenders with institutional quality yield overcollateralized by digital assets. The protocol combines the best of institutional lending and DeFi. Syrup is the team's newest product, offering permissionless access to Maple's lending engine whilst also integrated with the broader DeFi ecosystem including Balancer and Pendle Finance.

Syrup

SYRUP is experiencing heightened attention following a recent high-profile exchange listing and its strong positioning as a Real World Asset (RWA) and tokenization leader. The community widely views the asset as significantly undervalued compared to similar projects, anticipating a substantial repricing as institutional engagement in DeFi continues to expand. Discussion also centers on Maple Finance's strategic shift to a revenue-driven token buyback model, which is seen as a key catalyst.

PulteGroup, Inc. engages in the homebuilding business. The firm is also involved in mortgage banking and title and insurance brokerage operations. It operates through the Homebuilding and Financial services business segments. The Homebuilding segment includes operations from Connecticut, Maryland, Massachusetts, New Jersey, New York, Pennsylvania, Virginia, Georgia, North Carolina, South Carolina, Tennessee, Florida, Illinois, Indiana, Kentucky, Michigan, Minnesota, Missouri, Ohio, Texas, Arizona, California, Nevada, New Mexico, and Washington. The Financial Services segment is composed of mortgage banking and title operations. The company was founded by William J. Pulte in 1950 and is headquartered in Atlanta, GA.

PulteGroup Inc

PulteGroup is trending following strong quarterly financial results and significant share repurchase authorizations, signaling management confidence in its operational model. The community remains divided, with some anticipating sustained demand from structural housing shortages and potential mortgage rate relief, while others express caution regarding persistent affordability challenges and sector-wide margin pressures due to incentives.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$CVM Has 1 year from the primary completion date to submit data to the FDA for the Multikine trial (which would be submitted to us as well). Primary completion date was May 15, 2020. So only 11 days left. Does anyone have any knowledge to whether Cel Sci would be required to disclose to investors if they did get an extension for this regulation? Thank you in advance.

STEVE SMITH

StockTwits Web

Cel-Sci Corp

 Has 1 year from the primary completion date to submit data to the FDA for the Multikine trial (which would be submitted to us as well). Primary completion date was May 15, 2020. So only 11 days left. Does anyone have any knowledge to whether Cel Sci would be required to disclose to investors if they did get an extension for this regulation? Thank you in advance.

Gator

@protradergator This theory has been debunked a few times on this board.  May 15, 2021 means nothing

83Bucks

Martin van Nostrand

La_Oveja_Negra

 This theory has been debunked a few times on this board.  May 15, 2021 means nothing

Ariel Diaz

@Adiaz0505 How has it been debunked? It&#39;s not necessarily a theory based off what I found: https://medschool.duke.edu/sites/medschool.duke.edu/files/field/attachments/ctgov_what%20are%20completion%20dates%20Tip%20Sheet_20150519_1.pdf

&quot;For Applicable Clinical Trials, results must be entered 1 year after the Primary Completion Date. Required data includes results for the Primary Outcome Measure, participant flow (the number of participants who started, completed, and dropped out of each period of the study), baseline demographics and adverse event/serious adverse event data.&quot;

R.J.

Duke

 How has it been debunked? It's not necessarily a theory based off what I found: 



"For Applicable Clinical Trials, results must be entered 1 year after the Primary Completion Date. Required data includes results for the Primary Outcome Measure, participant flow (the number of participants who started, completed, and dropped out of each period of the study), baseline demographics and adverse event/serious adverse event data."

@protradergator Elaboration: Checklist for Evaluating Whether a Clinical Trial or Study is an Applicable Clinical Trial (ACT)
Under 42 CFR 11.22(b) for Clinical Trials Initiated on or After January 18, 2017

https://prsinfo.clinicaltrials.gov/ACT_Checklist.pdf

Untrade Warrior

Clinicaltrials

 Elaboration: Checklist for Evaluating Whether a Clinical Trial or Study is an Applicable Clinical Trial (ACT)
Under 42 CFR 11.22(b) for Clinical Trials Initiated on or After January 18, 2017



@Adiaz0505 so is it a applicable clinical trial or not?

 so is it a applicable clinical trial or not?